Kudlacek, Stefan <br/><br/>
[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].  [electronic resource] 

 -  Wiener medizinische Wochenschrift (1946)  Sep 2012 
 - 380-5 p.  digital 
<br/><br/> Publication Type: Case Reports; Comparative Study; English Abstract; Journal Article; Review 
<br/><br/><label>ISSN: </label>1563-258X 
<br/><br/><label>Standard No.: </label>10.1007/s10354-012-0106-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged, 80 and over<br/>Androgen Antagonists--adverse effects<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antineoplastic Agents, Hormonal--adverse effects<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--adverse effects<br/>Denosumab<br/>Diphosphonates--adverse effects<br/>Gonadotropin-Releasing Hormone--agonists<br/>Humans<br/>Male<br/>Neoplasm Staging<br/>Osteoclasts--drug effects<br/>Osteoporosis--chemically induced<br/>Osteoporotic Fractures--chemically induced<br/>Prostatic Neoplasms--drug therapy<br/>RANK Ligand--antagonists & inhibitors<br/>Randomized Controlled Trials as Topic<br/>Selective Estrogen Receptor Modulators--adverse effects<br/>Spinal Fractures--chemically induced<br/>Toremifene--adverse effects